CY1111063T1 - Καθολικος οδηγος gas1 - Google Patents
Καθολικος οδηγος gas1Info
- Publication number
- CY1111063T1 CY1111063T1 CY20101101090T CY101101090T CY1111063T1 CY 1111063 T1 CY1111063 T1 CY 1111063T1 CY 20101101090 T CY20101101090 T CY 20101101090T CY 101101090 T CY101101090 T CY 101101090T CY 1111063 T1 CY1111063 T1 CY 1111063T1
- Authority
- CY
- Cyprus
- Prior art keywords
- heavy chain
- chain variable
- variable domain
- immunoglobulin heavy
- domain polypeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
- C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/055—Fusion polypeptide containing a localisation/targetting motif containing a signal for localisation to secretory granules (for exocytosis)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Gas Separation By Absorption (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Αποκαλύπτεται ένα πολυνουκλεοτιδικό μόριο που αποτελείται από έναν υποκινητή που συνδέεται λειτουργικά με μια αλληλουχία νουκλεϊνικού οξέος που κωδικοποιεί ένα σηματοδοτικό πεπτίδιο έκκρισης GAS1, όπου ο αναφερόμενος υποκινητής δεν είναι υποκινητής ραμνόζης.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55576404P | 2004-03-24 | 2004-03-24 | |
EP05729650A EP1737962B1 (en) | 2004-03-24 | 2005-03-24 | Gas1 universal leader |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1111063T1 true CY1111063T1 (el) | 2015-06-11 |
Family
ID=34963448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20101101090T CY1111063T1 (el) | 2004-03-24 | 2010-11-29 | Καθολικος οδηγος gas1 |
Country Status (11)
Country | Link |
---|---|
US (1) | US7846721B2 (el) |
EP (2) | EP2172553A1 (el) |
AT (1) | ATE479760T1 (el) |
CY (1) | CY1111063T1 (el) |
DE (1) | DE602005023291D1 (el) |
DK (1) | DK1737962T3 (el) |
ES (1) | ES2351509T3 (el) |
PL (1) | PL1737962T3 (el) |
PT (1) | PT1737962E (el) |
SI (1) | SI1737962T1 (el) |
WO (1) | WO2005093074A1 (el) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005311099B2 (en) | 2004-12-02 | 2012-02-02 | Domantis Limited | Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY |
CA2688433A1 (en) | 2007-06-06 | 2008-12-11 | Domantis Limited | Methods for selecting protease resistant polypeptides |
SG194383A1 (en) | 2008-12-05 | 2013-11-29 | Glaxo Group Ltd | Methods for selecting protease resistant polypeptides |
SG173489A1 (en) | 2009-02-19 | 2011-09-29 | Glaxo Group Ltd | Improved anti-serum albumin binding variants |
CN102405232B (zh) | 2009-02-19 | 2015-08-19 | 葛兰素集团有限公司 | 改良的抗血清清蛋白结合变体 |
EA022925B1 (ru) | 2009-02-19 | 2016-03-31 | Глаксо Груп Лимитед | Улучшенные полипептиды, вариабельные домены антител и антагонисты против tnfr1 |
CA2768462A1 (en) | 2009-07-16 | 2011-01-20 | Glaxo Group Ltd. | Improved anti-serum albumin binding single variable domains |
EP2453920A2 (en) | 2009-07-16 | 2012-05-23 | Glaxo Group Limited | Antagonists, uses & methods for partially inhibiting tnfr1 |
BR112012001977A2 (pt) | 2009-07-29 | 2017-01-31 | Glaxo Group Ltd | domínio variável único de imunoglobulina, polipeptídeo isolado, ligante, proteína de fusão, ácido nucleico isolado, molécula de ácido nucleico isolado, vetor, célula hospedeira, métodos para produzir um polipeptídeo e para tratar e/ou prevenir uma condição, composição farmacêutica, uso de um domínio variável único, e, dispositivo de dispensação pulmonar. |
WO2011086143A2 (en) | 2010-01-14 | 2011-07-21 | Glaxo Group Limited | Liver targeting molecules |
EP2560992A2 (en) | 2010-04-21 | 2013-02-27 | Glaxo Group Limited | Binding domains |
US9040668B2 (en) | 2010-05-20 | 2015-05-26 | Glaxo Group Limited | Anti-serum albumin binding variants |
EP2603607B1 (en) * | 2010-08-11 | 2016-04-06 | Celula, Inc. | Genotyping dna |
JP2013538566A (ja) | 2010-08-13 | 2013-10-17 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 改良された抗血清アルブミン結合変異体 |
KR20130055663A (ko) | 2010-08-20 | 2013-05-28 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 개선된 항-혈청 알부민 결합 변이체 |
JP6062375B2 (ja) | 2011-01-06 | 2017-01-18 | グラクソ グループ リミテッドGlaxo Group Limited | Tgf−ベータ受容体iiに結合するリガンド |
JP2014505698A (ja) | 2011-02-02 | 2014-03-06 | グラクソ グループ リミテッド | 新規抗原結合タンパク質 |
MY165090A (en) | 2011-04-21 | 2018-02-28 | Bristol Myers Squibb Co | Antibody polypeptides that antagonize cd40 |
CA2877009C (en) * | 2012-07-05 | 2023-10-03 | Devin TESAR | Expression and secretion system |
US10435475B2 (en) | 2014-03-07 | 2019-10-08 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize CD40 to treat IBD |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9400600A (pt) * | 1994-02-17 | 1995-10-24 | Finep Financiadora De Estudos | Processos para produção de uma protéina recombinante e/ou de glicosilfosfatidilinositol (GPI) em células de microorganismos eucariontes e para a obtenção de leveduras de S. cerevisae; célula de levedura sequência de nucleotídios; meio de cultura; medicamento ou vacina; e produto dos ditos processos |
US6555310B1 (en) * | 1997-04-04 | 2003-04-29 | Biosite Diagnostics, Inc. | Polyclonal libraries |
US7094579B2 (en) * | 2002-02-13 | 2006-08-22 | Xoma Technology Ltd. | Eukaryotic signal sequences for prokaryotic expression |
-
2005
- 2005-03-24 PT PT05729650T patent/PT1737962E/pt unknown
- 2005-03-24 DE DE602005023291T patent/DE602005023291D1/de active Active
- 2005-03-24 ES ES05729650T patent/ES2351509T3/es active Active
- 2005-03-24 SI SI200531167T patent/SI1737962T1/sl unknown
- 2005-03-24 EP EP09155173A patent/EP2172553A1/en not_active Withdrawn
- 2005-03-24 DK DK05729650.1T patent/DK1737962T3/da active
- 2005-03-24 EP EP05729650A patent/EP1737962B1/en not_active Not-in-force
- 2005-03-24 PL PL05729650T patent/PL1737962T3/pl unknown
- 2005-03-24 WO PCT/GB2005/001180 patent/WO2005093074A1/en active Application Filing
- 2005-03-24 AT AT05729650T patent/ATE479760T1/de active
-
2006
- 2006-07-27 US US11/494,965 patent/US7846721B2/en not_active Expired - Fee Related
-
2010
- 2010-11-29 CY CY20101101090T patent/CY1111063T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
US20070026462A1 (en) | 2007-02-01 |
EP1737962A1 (en) | 2007-01-03 |
US7846721B2 (en) | 2010-12-07 |
DK1737962T3 (da) | 2010-12-13 |
DE602005023291D1 (de) | 2010-10-14 |
EP2172553A1 (en) | 2010-04-07 |
ES2351509T3 (es) | 2011-02-07 |
SI1737962T1 (sl) | 2011-01-31 |
WO2005093074A1 (en) | 2005-10-06 |
PL1737962T3 (pl) | 2011-02-28 |
EP1737962B1 (en) | 2010-09-01 |
PT1737962E (pt) | 2010-12-03 |
ATE479760T1 (de) | 2010-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1111063T1 (el) | Καθολικος οδηγος gas1 | |
NZ734307A (en) | Antibodies specific for claudin 6 (cldn6) | |
DK1831362T3 (da) | Syreaktive svampeproteaser | |
EA200701443A1 (ru) | Синтетические домены иммуноглобулина, обладающие свойствами связывания и сконструированные в участках молекулы, отличных от гипервариабельных участков | |
ATE477336T1 (de) | Feste oberfläche für biomolekülabgabe und assay mit hoher durchlaufleistung | |
JP2014061000A5 (el) | ||
MX337991B (es) | Metodo para detectar cancer. | |
HK1097855A1 (en) | Method of detecting probnp with a monoclonal antibody binding to the amino acid 41-46 | |
ATE402267T1 (de) | Verfahren zur herstellung von monoklonalen antikörpern | |
BRPI0716997B8 (pt) | proteína ou composição de moléculas de proteína, métodos para produção e uso da mesma | |
DE502006009060D1 (de) | Verfahren zur fermentativen Herstellung von Antikörpern | |
DK1716178T3 (da) | Mindre immunogene bindingsmolekyler | |
ATE513788T1 (de) | Verfahren zur reinigung von lithiumsulfid | |
ATE514717T1 (de) | Rekombinante produktion von antikörpermischungen | |
NZ592308A (en) | Non-human mammals for the production of chimeric antibodies | |
WO2006116657A3 (en) | Single-chain antibody with cleavable linker | |
ATE441715T1 (de) | Streptococcus pyogenes antigene | |
DE602005016818D1 (de) | Verfahren zur charakterisierung einer polyklonalen zellinie | |
WO2004099376A3 (en) | Assays using amyloid precursor proteins with modified beta-secretase cleavage sites to monitor beta-secretase activity | |
DK1294876T3 (da) | EV-VEGF-nukleinsyrer og -polypeptider samt fremgangsmåder til deres benyttelse | |
DK1609863T3 (da) | Udskilte polypeptider og transmembranpolypeptider samt nucleinsyrer kodende for disse | |
ATE539163T1 (de) | Auf der verwendung von mva beruhende impfstoffe | |
ATE525642T1 (de) | Sensoranordnung und herstellungsverfahren für einen durch kapillareffekt gefüllten diagnose- sensor | |
ATE537133T1 (de) | Verfahren zur herstellung von olefin | |
DE60232346D1 (de) | Verfahren zur weithin ungestützten verbrennung von petroleumkoks |